-
- Albert Lo
- 1Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Liang-Chuan S. Wang
- 3Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- John Scholler
- 4Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- James Monslow
- 1Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Diana Avery
- 1Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Kheng Newick
- 3Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Shaun O'Brien
- 3Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Rebecca A. Evans
- 2Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- David J. Bajor
- 4Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Cynthia Clendenin
- 4Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Amy C. Durham
- 6Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Elizabeth L. Buza
- 6Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Robert H. Vonderheide
- 2Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Carl H. June
- 2Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Steven M. Albelda
- 2Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania.
-
- Ellen Puré
- 1Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, Pennsylvania.
書誌事項
- 公開日
- 2015-07-14
- DOI
-
- 10.1158/0008-5472.can-14-3041
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Malignant cells drive the generation of a desmoplastic and immunosuppressive tumor microenvironment. Cancer-associated stromal cells (CASC) are a heterogeneous population that provides both negative and positive signals for tumor cell growth and metastasis. Fibroblast activation protein (FAP) is a marker of a major subset of CASCs in virtually all carcinomas. Clinically, FAP expression serves as an independent negative prognostic factor for multiple types of human malignancies. Prior studies established that depletion of FAP+ cells inhibits tumor growth by augmenting antitumor immunity. However, the potential for immune-independent effects on tumor growth have not been defined. Herein, we demonstrate that FAP+ CASCs are required for maintenance of the provisional tumor stroma because depletion of these cells, by adoptive transfer of FAP-targeted chimeric antigen receptor (CAR) T cells, reduced extracellular matrix proteins and glycosaminoglycans. Adoptive transfer of FAP-CAR T cells also decreased tumor vascular density and restrained growth of desmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancers in an immune-independent fashion. Adoptive transfer of FAP-CAR T cells also restrained autochthonous pancreatic cancer growth. These data distinguish the function of FAP+ CASCs from other CASC subsets and provide support for further development of FAP+ stromal cell-targeted therapies for the treatment of solid tumors. Cancer Res; 75(14); 2800–10. ©2015 AACR.</jats:p>
収録刊行物
-
- Cancer Research
-
Cancer Research 75 (14), 2800-2810, 2015-07-14
American Association for Cancer Research (AACR)
